olmesartan has been researched along with Cirrhosis in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, EH; Choi, HS; Kim, CS; Kim, IJ; Kim, SW; Ma, SK; Scholey, JW; Suh, SH | 1 |
| Cui, X; Fu, M; Ge, J; Hu, K; Liao, J; Sun, A; Xu, J; Zhou, J; Zhu, H; Zou, Y | 1 |
| Chong, L; Chu, M; Huang, Y; Li, Y; Mei, L; Wu, L; Yang, X | 1 |
| Ichikawa, H; Kimura, Y; Kinjo, T; Narita, I; Nishizaki, K; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H | 1 |
| Cheng, XW; Izawa, H; Kim, W; Kobayashi, M; Kuzuya, M; Murohara, T; Nagata, K; Nishizawa, T; Obata, K; Okumura, K; Sasaki, T; Sato, K; Shi, GP; Yamada, T; Yokota, M | 1 |
| Dong, YF; Ichijo, H; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
| Fukamizu, A; Honjo, K; Inaba, S; Ishida, J; Nakamura, S; Sakairi, A; Sugiyama, F; Yagami, K | 1 |
| Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F | 1 |
| Geot, WM; Horikoshi, S; Suzuki, Y; Takahashi, H; Tanifuji, C; Tomino, Y | 1 |
| Kato, M; Mizuno, M; Sada, T; Terashima, H; Tsuchida, H; Yasumo, H | 1 |
| Chen, R; Eisner, C; Hu, X; Huang, Y; Kopp, JB; Leelahavanichkul, A; Mizel, D; Schnermann, J; Star, RA; Wright, EC; Yan, Q; Yuen, PS; Zhou, H | 1 |
| Hatipoglu, FO; Hirohata, S; Iwamoto, M; Kusachi, S; Miyoshi, T; Ninomiya, Y; Ogawa, H; Ohtsuki, T; Shinohata, R; Yamamoto, K | 1 |
| Ge, J; Guo, J; Jiang, G; Li, L; Wang, S; Wu, J; You, J; Zou, Y | 1 |
1 trial(s) available for olmesartan and Cirrhosis
| Article | Year |
|---|---|
Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Echocardiography, Doppler, Color; Female; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Inflammation; Male; Middle Aged; Myocardium; Severity of Illness Index; Tetrazoles; Time Factors; Treatment Outcome; Ventricular Function, Left | 2009 |
12 other study(ies) available for olmesartan and Cirrhosis
| Article | Year |
|---|---|
Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.
Topics: Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Apoptosis; Biomarkers; Biopsy; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Imidazoles; Kidney Tubules; Mice; Mice, Knockout; Nephritis, Hereditary; Peptidyl-Dipeptidase A; ras Proteins; Tetrazoles; Transforming Growth Factor beta; Treatment Outcome | 2019 |
Olmesartan attenuates cardiac hypertrophy and improves cardiac diastolic function in spontaneously hypertensive rats through inhibition of calcineurin pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Calcineurin; Cardiomegaly; Diastole; Down-Regulation; Fibrosis; Heart Rate; Hypertension; Imidazoles; Male; NFATC Transcription Factors; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles | 2014 |
Olmesartan ameliorates pressure overload-induced cardiac remodeling through inhibition of TAK1/p38 signaling in mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cells, Cultured; Fibroblasts; Fibrosis; Heart; Imidazoles; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Rats; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1 | 2016 |
Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression.
Topics: Animals; Blood Pressure; Cardiomegaly; Fibrosis; Gene Expression; Hydralazine; Imidazoles; Male; Mice; Myocytes, Cardiac; NADPH Oxidases; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Signal Transduction; Tetrazoles | 2016 |
Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cathepsins; Cells, Cultured; Fibrosis; Heart Failure; Humans; Hypertension; Imidazoles; Leucine; Myocardium; Myocytes, Cardiac; NADPH Oxidases; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Sodium Chloride; Superoxides; Tetrazoles; Ventricular Remodeling | 2008 |
Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Eating; Endothelium, Vascular; Fatty Liver; Fibrosis; Imidazoles; Insulin Resistance; Male; MAP Kinase Kinase Kinase 5; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; NADPH Oxidases; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Obesity; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1 | 2008 |
Angiotensin type 1 receptor blockade prevents cardiac remodeling in mice with pregnancy-associated hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomegaly; Disease Models, Animal; Female; Fibrosis; Hypertension, Pregnancy-Induced; Imidazoles; Male; Mice; Mice, Transgenic; Myocardium; Pregnancy; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Ventricular Remodeling | 2008 |
Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Azetidinecarboxylic Acid; Blotting, Western; Calcium Channel Blockers; Dihydropyridines; Drug Synergism; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Imidazoles; Immunohistochemistry; Kidney; Mice; NADPH Oxidases; Nitric Oxide Synthase Type III; Polycystic Kidney Diseases; Tetrazoles | 2009 |
A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzamides; Collagen; Collagen Type I; Collagen Type I, alpha 1 Chain; Dioxoles; Disease Models, Animal; Fibrosis; Genes, Reporter; Hydroxyproline; Imidazoles; Kidney; Luciferases; Male; Protein Serine-Threonine Kinases; Rats; Rats, Transgenic; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Sensitivity and Specificity; Tetrazoles; Ureteral Obstruction | 2010 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chronic Disease; Desoxycorticosterone; Disease Models, Animal; Disease Progression; Fibrosis; Genetic Predisposition to Disease; Glomerulonephritis; Heart Diseases; Hydralazine; Hypertension; Imidazoles; Infusion Pumps, Implantable; Infusions, Subcutaneous; Kidney; Kidney Diseases; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Nephrectomy; Sodium Chloride, Dietary; Species Specificity; Telemetry; Tetrazoles; Time Factors; X-Ray Microtomography | 2010 |
Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cardiomegaly; Connective Tissue Growth Factor; Echocardiography; Enzyme-Linked Immunosorbent Assay; Fibrosis; Heart; Hydralazine; Imidazoles; Immunohistochemistry; Male; Myocardium; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Transforming Growth Factor beta1 | 2010 |
Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium-Binding Proteins; Dipeptides; Disease Models, Animal; Fibrosis; Hypertrophy, Left Ventricular; Imidazoles; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Microcirculation; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Receptor, Notch1; Tetrazoles; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling | 2013 |